Kleresca® receives CE mark approval for the next generation biophotonic system in dermatology
Ballerup, Denmark, August 2018. Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, today announced they have received CE mark approval for their technology platform.For Kleresca®, the CE mark approval is the foundation for future expansion in both Europe, US, Canada and Australia. It confirms that the product meets the requirements of the European Medical Device Directive. “The CE mark approval is a significant accomplishment for Kleresca® as it is based on a quality management system that we have